|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCDC112 |
Gene summary for CCDC112 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCDC112 | Gene ID | 153733 |
| Gene name | coiled-coil domain containing 112 | |
| Gene Alias | MBC1 | |
| Cytomap | 5q22.3 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q8NEF3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 153733 | CCDC112 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.73e-03 | 3.52e-01 | -0.1954 |
| 153733 | CCDC112 | HTA11_696_2000001011 | Human | Colorectum | AD | 7.43e-06 | 3.15e-01 | -0.1464 |
| 153733 | CCDC112 | HTA11_6818_2000001011 | Human | Colorectum | AD | 8.90e-03 | 4.35e-01 | 0.0112 |
| 153733 | CCDC112 | A015-C-203 | Human | Colorectum | FAP | 1.27e-07 | -7.01e-02 | -0.1294 |
| 153733 | CCDC112 | A002-C-201 | Human | Colorectum | FAP | 3.63e-02 | -9.14e-02 | 0.0324 |
| 153733 | CCDC112 | A001-C-108 | Human | Colorectum | FAP | 9.78e-03 | -4.39e-02 | -0.0272 |
| 153733 | CCDC112 | A002-C-205 | Human | Colorectum | FAP | 5.14e-05 | -1.05e-01 | -0.1236 |
| 153733 | CCDC112 | A015-C-006 | Human | Colorectum | FAP | 1.74e-03 | -1.06e-01 | -0.0994 |
| 153733 | CCDC112 | A015-C-106 | Human | Colorectum | FAP | 2.06e-02 | -8.51e-02 | -0.0511 |
| 153733 | CCDC112 | A002-C-114 | Human | Colorectum | FAP | 1.33e-03 | -1.28e-01 | -0.1561 |
| 153733 | CCDC112 | A015-C-104 | Human | Colorectum | FAP | 2.78e-10 | -7.91e-02 | -0.1899 |
| 153733 | CCDC112 | A002-C-016 | Human | Colorectum | FAP | 8.25e-04 | -1.02e-01 | 0.0521 |
| 153733 | CCDC112 | A001-C-203 | Human | Colorectum | FAP | 5.87e-03 | 3.80e-02 | -0.0481 |
| 153733 | CCDC112 | A002-C-116 | Human | Colorectum | FAP | 9.13e-09 | -5.79e-02 | -0.0452 |
| 153733 | CCDC112 | A014-C-008 | Human | Colorectum | FAP | 1.64e-02 | -1.60e-01 | -0.191 |
| 153733 | CCDC112 | A018-E-020 | Human | Colorectum | FAP | 8.21e-04 | -6.26e-02 | -0.2034 |
| 153733 | CCDC112 | F034 | Human | Colorectum | FAP | 8.72e-05 | -1.17e-01 | -0.0665 |
| 153733 | CCDC112 | CRC-1-8810 | Human | Colorectum | CRC | 2.11e-02 | -2.32e-01 | 0.6257 |
| 153733 | CCDC112 | LZE24T | Human | Esophagus | ESCC | 4.67e-06 | 2.59e-01 | 0.0596 |
| 153733 | CCDC112 | P2T-E | Human | Esophagus | ESCC | 2.16e-09 | 2.21e-01 | 0.1177 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCDC112 | SNV | Missense_Mutation | novel | c.1580N>T | p.Arg527Ile | p.R527I | Q8NEF3 | protein_coding | deleterious_low_confidence(0.02) | benign(0.022) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CCDC112 | SNV | Missense_Mutation | c.1563G>C | p.Trp521Cys | p.W521C | Q8NEF3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A0XU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CCDC112 | SNV | Missense_Mutation | c.659C>A | p.Pro220His | p.P220H | Q8NEF3 | protein_coding | deleterious(0.01) | possibly_damaging(0.891) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| CCDC112 | SNV | Missense_Mutation | rs187304678 | c.214N>T | p.Arg72Cys | p.R72C | Q8NEF3 | protein_coding | deleterious(0.01) | probably_damaging(0.963) | TCGA-E2-A153-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| CCDC112 | insertion | Frame_Shift_Ins | novel | c.1351_1352insATGTAAATAAGTA | p.Leu451HisfsTer10 | p.L451Hfs*10 | Q8NEF3 | protein_coding | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| CCDC112 | insertion | Frame_Shift_Ins | novel | c.250_251insAATCCTCTCTTTCTTGTTATAT | p.Met84LysfsTer12 | p.M84Kfs*12 | Q8NEF3 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| CCDC112 | deletion | Frame_Shift_Del | novel | c.1398delN | p.Lys466AsnfsTer8 | p.K466Nfs*8 | Q8NEF3 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| CCDC112 | SNV | Missense_Mutation | novel | c.71N>A | p.Gly24Asp | p.G24D | Q8NEF3 | protein_coding | tolerated_low_confidence(0.39) | benign(0.039) | TCGA-DS-A1OA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
| CCDC112 | SNV | Missense_Mutation | rs185790295 | c.1178G>A | p.Arg393His | p.R393H | Q8NEF3 | protein_coding | tolerated(0.08) | benign(0.033) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| CCDC112 | SNV | Missense_Mutation | c.519N>C | p.Gln173His | p.Q173H | Q8NEF3 | protein_coding | deleterious(0.02) | probably_damaging(0.939) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |